GSK commits $800 million to a Pennsylvania biologics hub as pharma manufacturing moves closer to U.S. health systems
The Upper Merion site will combine commercial biologics production, a pilot plant and quality labs, part of GSK's $30 billion U.S. pledge through 2030. Construction starts in 2027, so supply effects are years out.
Article summary
- Why it matters: Pharmaceutical companies are adding U.S. capacity under pressure from tariffs and tax incentives. For health system and pharmacy procurement, more domestic biologics capacity should eventually mean less exposure to import tariffs and long supply lines, but not before the late 2020s.
- What to do first: Track supplier capacity roadmaps. Ask pharmaceutical suppliers where future supply for your key products will be made and when new U.S. capacity qualifies.
- Separate near-term and long-term risk. Tariff exposure on imported medicines is a 2026–2027 issue; new U.S. plants are a late-decade answer.
- $800M+
- investment in Upper Merion Township, Pennsylvania
- 300+
- new jobs expected over five years
- 2027
- construction start
- $30B
- GSK's U.S. supply chain and R&D pledge through 2030
On this page
The details
GSK will invest more than $800 million to expand its site in Upper Merion Township, Montgomery County, Pennsylvania, Gov. Josh Shapiro’s office announced. Existing buildings will be demolished and replaced with:
- A commercial-scale biologics manufacturing facility for clinical and commercial supply
- A quality control laboratory
- A pilot plant for technology and process development
GSK expects to create more than 300 jobs over five years and retain 4,500 existing jobs. Construction begins in 2027. Regis Simard, GSK’s global supply chain president, said the investment will help accelerate the development and supply of future medicines. The state says GSK is eligible for its manufacturing innovation deduction and manufacturing tax credit programs.
The project is GSK’s second $800 million Pennsylvania commitment in two years. In October 2024 it pledged the same amount to expand manufacturing and R&D in Lancaster County, creating 200 jobs; that was then its largest U.S. manufacturing investment. Both are part of a $30 billion commitment GSK made in 2025 to expand U.S. supply chain infrastructure and R&D through 2030. Eli Lilly and Johnson & Johnson have also invested in Pennsylvania as part of multibillion-dollar U.S. expansion plans. The administration has paired tariffs with targeted tax incentives to encourage this kind of reshoring, and Pennsylvania’s own manufacturing tax programs add to the pull.
The site plan in detail. According to the governor’s office, the Upper Merion project combines commercial production, R&D and digital capabilities on one campus: a commercial-scale biologics plant for clinical and commercial supply, a co-located R&D pilot plant for technology transfer and process development, and a centralized quality control lab with a manufacturing science and technology hub. The state says the Upper Merion and Lancaster County projects together total nearly $1.7 billion.
Pennsylvania’s pitch. The state counts about 3,900 life sciences companies employing more than 110,000 people. Its 2026–27 budget includes $125 million for life sciences programs covering clinical trial infrastructure, workforce training and collaborative development grants. “GSK could have chosen anywhere in the world to expand production,” Gov. Shapiro said.
The company behind it. GSK, formed in 2000 from the merger of Glaxo Wellcome and SmithKline Beecham, rebranded in 2022 and spun off its consumer health business as Haleon, according to Manufacturing Dive. Its U.S. headquarters is in Philadelphia, and its portfolio includes medicines and vaccines for HIV, malaria and women’s cancers. The Upper Merion expansion qualifies for Pennsylvania’s Qualified Manufacturing Innovation and Reinvestment Deduction program and its Manufacturing Tax Credit program; the value of the incentives wasn’t disclosed.
Why biologics capacity takes so long
Biologics are made from living cells, so a new plant must be built, validated and approved before it can supply patients. Construction alone typically takes years, followed by process validation and regulatory inspection. Construction in Upper Merion starts in 2027, so supply from the site is unlikely before the end of the decade, in our assessment. Procurement teams should plan around today’s supply network for at least the next several contract cycles.
How to read a reshoring announcement
Plant announcements vary widely in how much they commit. When a supplier announces new U.S. capacity, procurement and supply chain teams can test it against five questions:
| Question | Why it matters | GSK Upper Merion |
|---|---|---|
| Is the investment amount and site named? | Shows a firm decision | Yes: more than $800 million, Upper Merion Township |
| Is there a construction start date? | Separates plans from projects | 2027 |
| Are specific products named? | Tells you whether your products will benefit | Not disclosed |
| Is there a date for commercial supply? | Sets when sourcing can change | Not disclosed |
| Are incentives tied to milestones? | Signals how firm the commitment is | Eligible for state tax programs |
This checklist is ours. Most announcements, including this one, name the site and the money but not the products or the date commercial supply begins, which is what procurement needs to plan around.
The investment per job. By our calculation, the project works out to roughly $2.7 million of investment for each of the more than 300 new jobs. That is typical of advanced pharmaceutical manufacturing, which is capital-intensive and highly automated, and a reminder that these plants add supply capacity far faster than they add local employment.
Questions to ask pharmaceutical suppliers
- Where are the products we buy from you made today, including active ingredients?
- Which of them will move to new U.S. capacity, and when do you expect regulatory approval for that site?
- Do you have a tariff agreement with the U.S. government, and how does it affect our pricing?
- How will you allocate supply during the transition between sites?
- Will you notify us before changing the manufacturing site for any product we buy?
How to factor reshoring into pharmaceutical sourcing
| Time frame | What changes | What to do |
|---|---|---|
| 2026 to 2027 | Section 232 tariffs apply to patented imports; generics exempt for now | Map products by origin and supplier agreement |
| 2027 to 2029 | New U.S. plants under construction; supplier tariff deals change rates | Add rate-change clauses; re-check supplier status quarterly |
| 2029 onward | New capacity begins to qualify; some tariff discounts expire | Revisit dual sourcing and origin requirements in long-term contracts |
What procurement teams should do
- Track supplier capacity roadmaps. Ask pharmaceutical suppliers where future supply for your key products will be made and when new U.S. capacity qualifies.
- Separate near-term and long-term risk. Tariff exposure on imported medicines is a 2026–2027 issue; new U.S. plants are a late-decade answer.
- Use origin in contracts. Where possible, specify country of origin and tariff pass-through rules in pharmaceutical supply agreements. See our coverage of Section 232 pharma tariffs.
What to watch next
- Construction start in 2027. Track whether the project begins on schedule; biologics plants take years to build and qualify.
- More pharma onshoring. Further announcements under company tariff agreements will shift where future supply is made.
- Section 232 pharma rates. Company-specific onshoring commitments can lower tariff rates for that supplier’s products.
The bigger picture
The onshoring wave in life sciences is real but slow. Procurement teams should treat announcements like this as signals for supplier risk models, not as reasons to relax current contingency plans.
Questions procurement teams are asking
What will GSK build in Upper Merion, Pennsylvania?
A single-site hub with a commercial-scale biologics manufacturing facility for clinical and commercial supply, a quality control lab and a pilot plant for technology and process development.
When will the new GSK capacity affect supply?
Not soon. Construction begins in 2027, and biologics facilities typically take years to build and qualify, so near-term sourcing plans should not assume the new capacity.
How much has GSK committed to U.S. manufacturing?
GSK committed $30 billion in 2025 to U.S. supply chain infrastructure and R&D through 2030. That includes $800 million for Lancaster County, Pennsylvania, announced in 2024, and more than $800 million for Upper Merion, Pennsylvania, announced in October 2026.
When will GSK's new Pennsylvania biologics plant start supplying medicines?
Construction begins in 2027. Biologics plants take years to build, validate and approve, so supply from the site is unlikely before the end of the decade, in our assessment.
How much is GSK investing in Pennsylvania?
More than $800 million at Upper Merion, on top of an $800 million Lancaster County commitment in 2024. The state says the two projects total nearly $1.7 billion, part of GSK's $30 billion U.S. commitment through 2030.
How we reported this
This story draws on 3 sources, listed below, and reflects figures as reported on October 14, 2026. The sections on why it matters and what procurement teams should do are Procurement Signal analysis. It is not legal or financial advice. See our editorial standards.
